Afluxin® for adults with gastroesophageal reflux disease (GERD)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study will give enrolled adults with symptomatic GERD either Afluxin® or a placebo and monitor symptom changes and safety outcomes. Eligible participants are aged 18–75 and must not have used PPIs, H2RAs, antacids, alginates, or substance-based GERD devices in the week before screening. The trial will collect clinical symptom data and safety information while participants are treated at participating centers. Study visits are being conducted at multiple university-affiliated hospitals in Italy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male and female patients, aged ≥ 18 years and ≤ 75 years.
2. Evidence of symptomatic GERD: patients with ongoing heartburn and/or regurgitation (with or without dyspepsia symptoms of epigastric pain and/or burning) of at least mild to moderate severity or experienced during the least 7 days before starting the treatment, as assessed on a clinical basis by the Investigator.
3. Patients not pre-treated with PPIs, even for problems different from GERD (e.g., gastroprotection, PPI-based triple or quadruple therapy for eradication of H. pylori), H2RAs, and/or with antiacids, alginates or medical devices made of substances (i.e., substance-based medical devices to treat GERD, gastroesophageal reflux and similar conditions) in the last week prior to screening.
4. Patient has provided written informed consent after being informed of the study procedures and risks prior to any study-related events.
5. Patients are able to understand and adhere to the study procedures.
6. Females of childbearing potential must have a negative urine pregnancy test (dipstick) at Visit 1 and currently use or agree to use consistently and correctly (i.e., perfect use) a highly effective or acceptable effective contraceptive method for the individual subject and her partner(s) throughout the study treatment period.

Exclusion Criteria:

1. Patient with hypersensitivity to any Afluxin® or inactive control components.
2. Rhinosinusitis or bronchitis.
3. Patients with a:

   1. history and/or
   2. symptom profile and/or
   3. discovered on endoscopy suggestive of the following: any other Gastrointestinal (GI) disease, erosive GERD, BE, acute peptic ulcer and/or ulcer complications, hiatus hernia with a diameter which exceeds 3 cm, Zollinger-Ellison syndrome, esophageal or gastric cancer, pyloric stenosis, esophageal or gastric surgery, intestinal obstruction, current pernicious anemia, indication for H. pylori eradication therapy, known gastro-intestinal bleeding (hematochezia or hematemesis) within the last 12 months.
4. Patients diagnosed with functional dyspepsia characterized by postprandial distress syndrome (i.e., bothersome postprandial fullness and/or early satiation).
5. Patients with a history of gastro-esophageal surgery, anti-reflux, or bariatric procedure.
6. Presence of any active malignancy (except for non-invasive basal or squamous cell carcinoma of the skin).
7. Patients using any drug that could affect symptoms or affecting the gastrointestinal tract during the last week prior to screening:

   1. prokinetics
   2. systemic glucocorticosteroids
   3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
8. Patients who are pregnant or lactating.
9. Patients who are enrolled in or have participated in other clinical trials or investigations within 30 days prior to screening.
10. Clinically significant or unstable concurrent diseases whose sequelae or treatment might contraindicate study participation or interfere with the study evaluation parameters, as judged by the Investigator.

Where it's running

• IRCCS Policlinico San Martino
  Genova, Italy Recruiting
• IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation
  Milan, Italy Recruiting
• AOU Federico II di Napoli
  Naples, Italy Recruiting
• Azienda Ospedale Università Padova
  Padova, Italy Recruiting
• S. Andrea Ospedale Universitario
  Roma, Italy Recruiting
• Humanitas Research Hospital
  Rozzano (MI), Italy Recruiting

Study contacts

• Study coordinator: Daniela Salvati
• Email: daniela.salvati@prineos.com
• Phone: +39 3334828012

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GERD patients: see how symptoms relate to posture, pain, and activity

  This study will look at whether people with GERD have different posture, pain levels, and activity compared with what their GERD symptoms suggest.

  Recruiting Karabuk University · Karabük, Karabük Province · NCT07643779

• Comparing Vonoprazan and Pantoprazole for Treating GERD

  This study tests whether a new medication called vonoprazan works better than pantoprazole for treating GERD symptoms in adults aged 17 to 60.

  Recruiting Phase 4 Tanta University · Giza · NCT06564246

• Registry to evaluate RefluxStop for treating GERD

  This study is testing the RefluxStop device to see if it safely helps people with GERD feel better compared to standard treatments.

  Recruiting at 5 sites Implantica CE Reflux Ltd. · Friedrichshafen and 5 other locations · NCT05870163

• Registry for gastrointestinal motility disorders at Indiana University

  This study is creating a detailed list of patients with gastrointestinal motility disorders to help doctors better understand and treat these conditions.

  Recruiting Indiana University · Indianapolis, Indiana · NCT04506593

• Registry for identifying risk factors of esophageal cancer

  This study is trying to find out if certain blood and tissue markers can help identify people at risk for esophageal cancer by looking at their medical history and samples.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT00260585

• Quality sleep improvement with evening topical therapy for nocturnal GERD

  This trial tests a medical device given before bed to see if it reduces nighttime GERD symptoms and improves sleep and quality of life in adults with nocturnal reflux.

  Recruiting Cellmedis · Warsaw, Masovian Voivodeship and 1 other locations · NCT07700342

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.